Orgenesis Inc.
Cell and gene therapies (CGTs) use modified cells or cellular matter to treat, prevent or cure serious health issues like cancer, genetic disorders, immunodeficiencies, rare diseases, and more. CGTs have shown potential to replace damaged cells with functional alternatives or to elicit a desired immune response. Despite this great potential, CGTs have proven complex, expensive, and challenging to bring to market, in part because of the logistic hurdles associated with many of these personalized therapies. Our POCare Platform is shaping a CGT ecosystem to lower costs for innovators, accelerate treatments to market, and expand access for patients.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2012
- Employees:
- 101-1000
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
Unlocking the Potential of Cell and Gene Therapy for All
Personalized cell and gene therapies (CGTs) offer pofential to address the world's most challenging diseases. We are committed to helping to bring these advanced therapies to market effectively.
Bringing Advanced Therapies Within Reach
Providing advanced therapies to the patients who need them Is complex and expensive. The Orgenesls POCare Platform was designed to simplify this process with a unique approach to drug development and scale-up.
Our team has forged relationships within the blotech Industry and with top academla, research Institutes and hospitals to commercialize point of care therapies across the globe.
Orgenesis works to make therapies commercially accessible
An Ecosystem of Innovation
Our POCare Platform Is shaping a CGT ecosystem to lower costs, accelerate treatments to market and expand access for patients.
We have internal development and services centers and global partner locations where we leverage our expertise with highly scalable and cost-effective solutions to advance a pipeline of owned and partnered technologies for point of care production.
Working with us means immediate access to the know-how that has the potential to commercialize therapies and them to the patients who need them.
Making Cell & Gene Therapies a Reality
In 2019, there were over 1,000 cell and gene therapy related clinical trials ongoing globally. But most of these biotechnology companies and research institutes lack the expertise to scale their development and manufacturing operations to make them accessible and affordable.
We work to overcome existing challenges of CGT production with process development, manufacturing systems, logistics, and regulatory expertise.
